What question did this study set out to answer?

To determine the effectiveness of tetracosactide in treating postdural puncture headaches in postpartum women.

March 7, 2026

No Effect of Tetracosactide for Treatment of Postdural Puncture Headaches in Parturient Women: A Double-blind Randomized Controlled Clinical Trial

Key Points

To determine the effectiveness of tetracosactide in treating postdural puncture headaches in postpartum women.
Randomized, double-blind, placebo-controlled trial
Conducted in two tertiary maternal hospitals
Evaluated a single intravenous dose of tetracosactide against placebo
No significant reduction in the need for epidural blood patch after tetracosactide administration
Indicates limited efficacy of tetracosactide in addressing postdural puncture headaches
Findings suggest that standard treatments remain more effective

Abstract

( Br J Anaesth . 2025;135:148-154 doi: 10.1016/j.bja.2025.04.012) This randomized, double-blind, placebo-controlled clinical trial investigated whether tetracosactide, a synthetic analogue of adrenocorticotropic hormone (ACTH), could effectively treat postdural puncture headache (PDPH) in postpartum women who received neuraxial anesthesia. Conducted at 2 tertiary maternal hospitals in France, the study sought to evaluate if a single intravenous dose of tetracosactide could reduce the need for an epidural blood patch (EBP), the current gold-standard invasive treatment for PDPH.

Demander à l'IA

Bookmark

View Full Paper